RYTM enters its June 24 earnings report with a notable split: short sellers have been quietly trimming positions, while options traders have swung to their most bullish stance in months.
The options picture is the sharpest signal this week. The put/call ratio has collapsed to 0.32, nearly 2.7 standard deviations below its 20-day average of 0.47 — meaning call demand is running far above recent norms. That's the most aggressively bullish options positioning the stock has seen in recent months, sitting close to its 52-week low of 0.08 on the PCR scale. This shift accelerated over the past two sessions, with the ratio dropping sharply from 0.51 at the start of the week. Against that backdrop, the borrow market tells a relaxed story: availability is extremely loose at 2,831% — nearly 48 million shares available for lending versus roughly 7.9 million currently shorted — and cost to borrow remains near negligible at 0.43%. There is no short-squeeze pressure here; the bullish options lean reflects genuine call buying, not covering dynamics.
Short interest itself adds nuance rather than alarm. At 11.8% of free float, it remains elevated in absolute terms — a meaningful residual short position for a mid-cap biotech. But the direction of travel is clearly lower: shorts are down about 1.4% on the week and roughly 2.5% over the past month, receding from a peak above 8.3 million shares in early May. The ORTEX short score holds steady around 60-61, a mid-range reading that reflects the size of the position without signalling an escalating bear conviction.
The Street remains broadly constructive, though the most recent analyst moves are dated roughly five to six weeks ago. Following the May 5 earnings beat — the stock jumped nearly 13% on the day and held most of those gains into the subsequent week — Canaccord Genuity, RBC Capital, and Wells Fargo all nudged targets modestly higher, to $143, $137, and $144 respectively, while maintaining positive ratings. The consensus mean target runs near $138, implying roughly 56% upside to the current price of $88.38. Bulls anchor their case on Imcivree's expanding label, European and Japanese approvals, a planned Germany launch by 2027, and a total addressable market the company estimates at 27,000 additional patients beyond the current commercial base. Bears point to clinical execution risk, reimbursement uncertainty, and competition developing in the MC4R pathway space. The forward EPS growth score ranks in the 82nd percentile — the strongest factor in the profile — while short score rank sits in the 23rd percentile, reflecting how much short interest the stock carries relative to peers.
Institutional ownership provides a stable foundation. RA Capital holds the largest disclosed stake at around 9.7% of shares, unchanged at the March quarter-end. Baker Bros., another specialist life-sciences manager, holds a further 8.2%. Both are long-term holders with deep sector expertise, and neither trimmed in the last reported period. Westfield Capital added aggressively in the May reporting period, adding roughly 662,000 shares. Citadel also built a new position of about 1.3 million shares in Q1. The Chief Accounting Officer made modest routine sales in February and May — low-significance transactions that follow a typical plan-sale pattern and carry no thematic weight.
The last two earnings events show a stark contrast: the May print produced a 13% single-day rally, while the February release saw the stock fall 6.5% and drift a further 1.3% over the following week. With the June 24 event roughly ten days away, the call-heavy options positioning and easing short interest suggest the market is tilting toward optimism — the setup heading into the next print is therefore less about Imcivree's existing commercial trajectory and more about whether the company can offer credible detail on the Germany launch timeline and any progress on the Prader-Willi Syndrome indication.
See the live data behind this article on ORTEX.
Open RYTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
